SCN2A Antibody

What is SCN2A and why is it important in neuroscience research?

SCN2A encodes the neuronal sodium channel NaV1.2, which is essential for the initiation and propagation of action potentials in neurons. The channel is widely expressed throughout the human central nervous system but not in peripheral tissues . SCN2A has gained significant research attention because mutations in this gene are associated with epilepsies, intellectual disability, and autism spectrum disorders . There are two major developmentally regulated splice isoforms of NaV1.2 that differ by one amino acid at position 209: Asparagine (Asn/N) vs. Aspartic acid (Asp/D) .

What applications can SCN2A antibodies be used for?

SCN2A antibodies can be utilized in multiple experimental applications, including:

The optimal dilution should be determined empirically for each experimental system .

What species reactivity should I consider when selecting an SCN2A antibody?

• Proteintech antibody 27551-1-AP shows reactivity with human and mouse samples

• ABIN7043641 has been tested for reactivity with human, rat, and mouse samples

• Some antibodies are specific to just one species

Always check the manufacturer's validation data for your specific species of interest before selection .

What is the molecular weight of SCN2A protein in Western blot applications?

The calculated molecular weight of SCN2A is approximately 228 kDa, but the observed molecular weight in Western blot is typically around 250 kDa due to post-translational modifications . This discrepancy is normal and expected for this protein. Always include appropriate positive controls when first testing a new antibody to confirm band specificity .

How should I optimize Western blot protocols for SCN2A detection?

Optimizing Western blot for SCN2A requires special consideration due to its high molecular weight:

• Use low percentage (6-8%) SDS-PAGE gels to allow proper separation of high molecular weight proteins

• Extend transfer time (often overnight at low voltage) to ensure complete transfer of large proteins

• Block with 5% non-fat milk or BSA in TBST

• Primary antibody incubation can range from 1:500 to 1:2000 dilution, with overnight incubation at 4°C being common

• Include appropriate positive controls (e.g., brain tissue lysates, HEK-293 cells transfected with SCN2A)

• Consider using a blocking peptide control to confirm specificity

For example, Western blot analysis of rat brain membranes shows successful detection at 1:200 dilution with the Anti-SCN2A (NaV1.2) Antibody (#ASC-002) .

What are the best practices for immunofluorescence staining with SCN2A antibodies?

For optimal immunofluorescence results with SCN2A antibodies:

• Use freshly prepared or properly fixed tissue sections (4% paraformaldehyde is common)

• Include antigen retrieval steps if needed (citrate buffer pH 6.0 is often effective)

• Permeabilize tissue with 0.1-0.3% Triton X-100

• Block with 5-10% normal serum from the species of your secondary antibody

• Use antibody dilutions in the range of 1:50-1:500 for primary antibody

• Include co-staining with neuronal markers (like NeuN or MAP2) to confirm localization

• Always include negative controls (primary antibody omission) and positive controls

Immunohistochemical staining of mouse hippocampus shows NaV1.2 present in dendrites of pyramidal neurons in the CA3 region, with restricted localization to dendrites extending from the pyramidal layer .

How can I confirm the specificity of my SCN2A antibody?

To validate the specificity of SCN2A antibodies:

• Use genetic models: Test the antibody in SCN2A knockout or knockdown models to confirm reduced or absent signal

• Preabsorption controls: Preincubate the antibody with its immunizing peptide before application to samples

• Multiple antibodies: Test multiple antibodies targeting different epitopes of SCN2A

• Heterologous expression: Compare staining in cells overexpressing SCN2A versus control cells

• siRNA knockdown: Confirm reduced signal following SCN2A knockdown

• Compare with mRNA expression: Correlate protein expression with mRNA localization data

• Tissue specificity: Confirm strong staining in tissues known to express SCN2A (e.g., brain) and minimal staining in tissues that don't

For example, specificity can be confirmed by comparing Western blot analysis with and without preincubation with SCN2A/Nav1.2 Blocking Peptide .

How do pathogenic variants in SCN2A affect antibody detection and experimental design?

Pathogenic variants in SCN2A can significantly impact antibody detection, requiring special considerations:

• Epitope location: If the mutation affects the epitope region, antibody binding may be reduced or eliminated

• Protein expression levels: Many pathogenic variants cause reduced expression, requiring more sensitive detection methods

• Protein truncation: Nonsense mutations (like R102X) may result in truncated proteins that won't be detected by antibodies targeting downstream regions

• Subcellular localization: Some mutations alter trafficking, potentially changing localization patterns observed in immunostaining

For example, in iPSC-derived neurons from patients with intellectual disability, pathogenic ID variants caused a reduction in NaV1.2 protein level, requiring careful optimization of antibody concentration and detection methods .

What considerations are important when comparing SCN2A antibodies targeting different epitopes?

When comparing antibodies targeting different epitopes of SCN2A:

• Epitope accessibility: Epitopes in different protein domains may have varying accessibility in different applications

  • Antibodies targeting extracellular domains (like amino acids 51-150) are useful for non-permeabilized ICC

  • Antibodies targeting intracellular regions (like amino acids 467-485) require permeabilization

• Cross-reactivity with related channels:

  • NaV1.3 shares 12 out of 19 amino acid residues with NaV1.2 in the region targeted by some antibodies

  • Always check sequence similarity of the immunogen with other sodium channels

• Application-specific performance:

  • Some epitopes perform better in fixed tissues (IHC)

  • Others may be more suitable for denatured applications (WB)

• Recognizing developmental isoforms:

  • Ensure the antibody can detect both developmentally regulated splice isoforms if studying development

How can I use SCN2A antibodies to study developmental changes in expression patterns?

To study developmental changes in SCN2A expression:

• Select antibodies that recognize all relevant isoforms

• Use quantitative methods (Western blot with loading controls) to track expression levels

• Employ immunohistochemistry at different developmental timepoints to map spatial changes

• Consider co-staining with markers of neuronal maturation

• Compare with mRNA expression data from developmental transcriptome datasets

• Use proper age-matched controls for each developmental stage

Research has shown important developmental regulation of NaV1.2, with two major splice isoforms that use mutually exclusive copies of the fifth coding exon . This developmental regulation is critical when studying SCN2A's role in neurodevelopmental disorders .

What methods can be used to distinguish between SCN2A and other sodium channel subtypes in complex tissues?

Distinguishing SCN2A from other sodium channels requires careful methodological approaches:

• Epitope selection: Choose antibodies targeting unique regions of SCN2A

• Co-localization studies: Compare with known distribution patterns of different channel subtypes

• Genetic approaches: Use knockout/knockdown models as negative controls

• Electrophysiological correlation: Combine immunostaining with electrophysiological characterization

• Pharmacological tools: Use subtype-specific channel blockers to correlate with antibody staining

• Western blot optimization: Different sodium channels have slightly different molecular weights

• Combined approaches: Use multiple antibodies targeting different epitopes

Nav channels are classified into two groups according to their sensitivity to Tetrodotoxin (TTX): TTX-sensitive (NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.6, and NaV1.7) and TTX-resistant (NaV1.5, NaV1.8, and NaV1.9) .

What are common challenges in detecting SCN2A and how can they be addressed?

Common challenges in SCN2A detection include:

• High molecular weight transfer issues:

  • Solution: Use gradient gels, extended transfer times, or specialized transfer systems for high MW proteins

• Low signal intensity:

  • Solution: Optimize antibody concentration, extend incubation time, use signal amplification systems

• Non-specific binding:

  • Solution: Increase blocking time/concentration, test different blocking agents, optimize antibody dilution

• Degradation during sample preparation:

  • Solution: Use fresh samples, include protease inhibitors, keep samples cold throughout preparation

• Background in immunohistochemistry:

  • Solution: Optimize blocking, increase washing steps, titrate antibody, use more selective secondary antibodies

• Variation in expression levels:

  • Solution: Normalize to housekeeping proteins, use larger sample sizes, consider developmental timing

How should SCN2A antibodies be validated in knockout or knockdown models?

Proper validation of SCN2A antibodies in genetic models involves:

• Using heterozygous models (Scn2a+/-) to observe reduced signal intensity

• Testing in homozygous models (Scn2a-/-) where available to confirm complete loss of signal

• Employing gene-trap knockout models with residual expression to assess antibody sensitivity

• Including wild-type littermate controls processed in parallel

• Validating across multiple applications (WB, IHC, etc.)

• Quantifying reduction in signal relative to reduction in mRNA/protein

• Testing inducible knockdown systems to control for developmental compensation

For example, researchers have validated antibodies using Scn2a+/- mice which show moderate protein reduction and Scn2a-/- which show undetectable levels in Western blot analysis .

How can I resolve contradictory results between different SCN2A antibodies?

When facing contradictory results between different antibodies:

• Compare epitope regions and determine if differential protein processing might explain discrepancies

• Test antibodies side-by-side on the same samples under identical conditions

• Include appropriate positive and negative controls for each antibody

• Validate each antibody independently using knockout tissues or blocking peptides

• Consider if post-translational modifications might affect epitope accessibility

• Use complementary techniques (e.g., RNA analysis, mass spectrometry) to resolve discrepancies

• Consult literature for known issues with specific antibodies

Contradictions often arise from differences in epitope accessibility, antibody sensitivity, or cross-reactivity with related sodium channels that share sequence homology .

What are appropriate storage and handling conditions for maximizing SCN2A antibody performance?

For optimal antibody performance:

• Store antibodies according to manufacturer recommendations:

  • Typically at -20°C for long-term storage

  • Avoid repeated freeze-thaw cycles by aliquoting upon receipt

• Follow manufacturer-specific buffer compositions:

  • Many SCN2A antibodies are stored in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

  • Some preparations include 0.1% BSA

• Handling best practices:

  • Briefly centrifuge vials before opening to collect all liquid

  • Use sterile technique when handling stock solutions

  • Return to recommended storage immediately after use

  • Keep cold during handling (on ice)

• Stability considerations:

  • Most antibodies remain stable for one year after shipment when properly stored

  • Some can be stored at 4°C for short periods (weeks) if frequently used

As indicated in product information, SCN2A antibodies can typically be stored at -20°C and remain stable for one year after shipment, with aliquoting being unnecessary for -20°C storage in many cases .

How are SCN2A antibodies used to study autism and epilepsy models?

SCN2A antibodies are crucial tools in studying autism and epilepsy models:

• Protein expression analysis:

  • Quantifying NaV1.2 levels in patient-derived models (iPSCs, organoids)

  • Comparing expression between affected and unaffected brain regions

• Localization studies:

  • Mapping channel distribution in neuronal subtypes

  • Tracking developmental trajectories of expression

  • Examining axon initial segment localization

• Combined with electrophysiology:

  • Correlating protein expression with functional changes in neuron excitability

  • Understanding genotype-phenotype relationships

• In animal models:

  • Validating haploinsufficiency in heterozygous models

  • Examining compensatory changes in other channel subtypes

  • Investigating therapeutic interventions

Studies have used SCN2A antibodies to demonstrate that pathogenic variants cause early-stage dysfunction in patient-derived neurons, with intellectual disability-causing variants consistently reducing NaV1.2 protein levels, neuronal sodium current density, and action potential firing .

What methodological approaches combine SCN2A antibodies with functional studies?

Integrative approaches combining antibody-based detection with functional studies include:

• Patch-clamp electrophysiology + immunocytochemistry:

  • Record from identified neurons, then fix and stain for SCN2A

  • Correlate channel expression with functional properties

• Calcium imaging + immunostaining:

  • Measure network activity, then immunostain for SCN2A

  • Link expression patterns to network functions

• CRISPR-edited models + antibody validation:

  • Generate isogenic cell lines with SCN2A mutations

  • Compare protein expression and localization

• Optogenetic stimulation + immunohistochemistry:

  • Manipulate specific neural circuits

  • Examine SCN2A expression in manipulated cells

• In vivo EEG + post-mortem immunohistochemistry:

  • Record seizure activity in animal models

  • Correlate with channel expression patterns

Recent research combined CRISPR-Cas9-corrected isogenic lines and immunodetection of SCN2A to investigate neurons at the morphological, electrophysiological, and transcriptomic levels, finding that pathogenic ID variants consistently caused a reduction in NaV1.2 protein level .

How do SCN2A expression patterns differ across brain regions and neuronal subtypes?

Understanding regional and cell-type specific expression patterns requires specialized immunohistochemical approaches:

• Brain region specificity:

  • NaV1.2 is widely expressed throughout the human central nervous system but not in peripheral tissues

  • Particularly prominent in excitatory neurons of the neocortex and hippocampus

  • Expression in the hippocampal CA3 region has been well-characterized

• Neuronal subtype patterns:

  • SCN2A is predominantly expressed in excitatory neurons rather than inhibitory neurons

  • NaV1.2 is present in dendrites of pyramidal neurons

  • Recent evidence suggests differential expression may regulate cortical excitatory neuron development

• Subcellular localization:

  • NaV1.2 shows specific localization to dendrites extending from the pyramidal layer

  • Developmental shift occurs in axon initial segment composition during maturation

• Co-localization approaches:

  • Double-labeling with interneuron markers (e.g., Parvalbumin) demonstrates the restriction of NaV1.2 to specific cell types

Immunohistochemical staining shows NaV1.2 is present in dendrites of pyramidal neurons in the CA3 region, while staining with interneuron markers demonstrates the restriction of NaV1.2 to dendrites extending from the pyramidal layer .